摘要
目的:高压氧(HBO)联合瑞舒伐他汀治疗对2型糖尿病(T2DM)合并冠心病(CHD)患者D-二聚体(D-D)、脂蛋白相关磷脂酶A2(Lp-PLA2)、超敏C反应蛋白(hs-CRP)水平的影响。方法:回顾性分析临沂市中心医院2019年7月至2021年7月收治的167例T2DM合并CHD患者的临床资料,依据治疗方式分为2组,其中行常规治疗结合单纯口服瑞舒伐他汀的78例患者为对照组,在此基础上联合HBO治疗的89例患者为研究组,比较2组患者的治疗有效率、血黏度及D-D、Lp-PLA2、hs-CRP水平。结果:研究组患者的治疗有效率[93.23%(83/89)]明显高于对照组[82.05%(64/78)],差异有统计学意义(P<0.05或P<0.01);治疗后,研究组患者血清D-D、Lp-PLA2、hs-CRP水平以及血黏度比对照组明显降低,差异有统计学意义(P<0.05或P<0.01)。结论:HBO联合瑞舒伐他汀治疗T2DM合并CHD患者,比单用瑞舒伐他汀能更有效地降低患者的D-D、Lp-PLA2、hs-CRP水平以及血黏度,具有更好的临床疗效。
Objective To investigate the effect of hyperbaric oxygen(HBO)combined with rosuvastatin on the levels of D-dimer(D-D),lipoprotein-associated phospholipase A2(Lp-PLA2),and high-sensitivity C-reactive protein(hs-CRP)in patients with type 2 diabetes mellitus(T2DM)combined with coronary heart disease(CHD).Method The clinical data of 167 T2DM patients combined with CHD admitted to Linyi Central Hospital from July 2019 to July 2021 were retrospectively analyzed.They were divided into two groups according to different treatment methods.The control group(n=78)was given conventional treatment and oral rosuvastatin,and the study group(n=89)was treated with HBO on the basis of the treatment in the control group.The effective rate,blood viscosity,and the levels of D-D,Lp-PLA2,and hs-CRP were compared between the two groups.Results After treatment,the effective rate in the study group[93.23%(83/89)]was significantly higher than that of the control group[82.05%(64/78)],and the difference was statistically significant(P<0.05 or P<0.01);the serum levels of D-D,Lp-PLA2,hs-CRP,and blood viscosity in the study group were significantly lower than those of the control group,and the differences were statistically significant(P<0.05 or P<0.01).Conclusion HBO combined with rosuvastatin in the treatment of T2DM patients combined with CHD can be more effective than using rosuvastatin alone in reducing D-D,Lp-PLA2,hs-CRP levels,and blood viscosity,thus achieving better clinical efficacy.
作者
陈彬
赵慧
刘成华
于海亮
Bin Chen;Hui Zhao;Chenghua Liu;Hailiang Yu(Cardiovascular Medicine Department,Linyi Central Hospital,Linyi 276400,China;Nephrology Department,Linyi Central Hospital,Linyi 276400,China)
出处
《中华航海医学与高气压医学杂志》
CAS
CSCD
2022年第3期331-335,共5页
Chinese Journal of Nautical Medicine and Hyperbaric Medicine
基金
山东省医药卫生科技发展计划项目(2019WS137)。
关键词
高压氧
瑞舒伐他汀
2型糖尿病
冠心病
血清炎性因子
Hyperbaric oxygen
Rosuvastatin
Type 2 diabetes mellitus(T2DM)
Coronary heart disease
Serum inflammatory factors
